- Research & Development
Our first compound is enzalutamide, an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within the tumor cell.1 Enzalutamide currently is approved in the United States, Europe and numerous other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC), and is being further developed* for earlier stages of prostate cancer, advanced breast cancer and hepatocellular carcinoma. To learn more about enzalutamide, click here.
Talazoparib (MDV3800), an orally available poly-ADP ribose polymerase, or PARP, inhibitor, is our second asset, and currently is in a Phase 3 clinical trial for the treatment of patients with gBRCA mutated breast cancer (i.e., advanced breast cancer in patients whose BRCA genes contain germline mutations). We are targeting a number of other solid tumor indications in which to investigate talazoparib, including breast (beyond gBRCA mutations), prostate, small cell lung, and ovarian cancers. To learn more about PARP Inhibitors and how they work, click here.
Our third asset is pidilizumab (MDV9300), an antibody with immune-mediated anti-tumor effects, which we licensed exclusive worldwide rights from CureTech, Ltd., in 2014. We plan to develop pidilizumab in diffuse large B-cell lymphoma and other hematologic malignancies, such as multiple myeloma.1The clinical significance of this mechanism of action is unknown.
*Enzalutamide is being developed in collaboration with Astellas.
**DLBCL — phase 2 potentially pivotal studyTop